The Effect of Curcumin Against Colistin-induced Nephrotoxicity

• Status: Recruiting
• Trial end date: 2024-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to investigate the possible nephroprotective effect of curcumin in critically ill patients receiving colistin.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: October 6 University
• Collaborator: Cairo University
• Treatments: Colistin; Curcumin

Criteria

Inclusion Criteria:

• All critically ill adult patients (18-65 years old) who are infected by MDR Gram-negative bacteria and require intravenous colistin therapy

Exclusion Criteria:

• Patients receiving intravenous colistin therapy for < 72 hours.

• Patients receiving renal replacement therapy (RRT).

• Patients with diseases that may contribute to renal impairment such as systemic lupus erythematosus, acute myocardial infarction, cancer, HIV infection, glucose-6-phosphate-dehydrogenase deficiency, or urinary tract stone.

• Pregnancy or breastfeeding.

• Known allergy to the study medications.

• Patients with chronic kidney diseases (creatinine clearance < 60 mg/dL).

• Elevated total liver enzymes (AST, and ALT) three times above the upper limit of normal.

• Patients with acute decompensated heart failure signs and symptoms requiring intravenous loop diuretics and/or intravenous inotropes and/or ACE inhibitors.

• Uncontrolled diabetes (Glycosylated hemoglobin (Hb A1C) >8%).

• Hypotensive patients defined as decrease in blood pressure less than 90/60 mm Hg.

• Recent use of vitamins with antioxidant properties such as beta carotene, vitamin E, vitamin C, selenium, or N-acetylcysteine or any other medications known to have nephroprotective activities.

• Patients receiving other nephrotoxic drugs at enrollment (e.g., aminoglycosides, vancomycin, or amphotericin B) or administration of contrast medium within 7 days.